CRT 2025

CRT PREDICTS | Stratified Randomization Study to Compare Different Duration of DAPT After Coronary Stenting in Either High or Low Bleeding Risk Populations

Moderator(s)

• 

  Gregg W. Stone, MD, FACC, MSCAI

  Physician
  Mount Sinai
  New York, New York, United States

  Disclosure(s): Abbott, Abiomed, Cardiovascular Systems Inc, Phillips, Vascular Dynamics, Pulnovo, V-wave: Research support to Mount Sinai Hospital (Ongoing); Apollo Therapeutics, Cardiac Success, Occlutech, Millennia Biopharma, RCE, Ablative Solutions, Abbott: Consultant (Terminated); Boehringer Ingelheim: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Cardiac Success, Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Valfix, Xenter: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Shockwave, Biosense-Webster, Bioventrix: Research support to Mount Sinai Hospital (Terminated); Valfix, Zoll, HeartFlow, Shockwave, Ancora, Impulse Dynamics, Adona Medical, Oxitope, HighLife, Elixir, Elucid Bio, Aria, Alleviant, FBR Medical: Consultant (Ongoing)
• 

  Ron Waksman, MD, MSCAI

  Director, Cardiovascular Research and Advanced Education
  MedStar Washington Hospital Center, MedStar Heart and Vascular Institute
  Washington, District of Columbia, United States

  Disclosure(s): Abbott Vascular: Grant/Research Support (Ongoing); Biotronik: Consultant (Ongoing), Grant/Research Support (Ongoing); Boston Scientific Corporation: Consultant (Ongoing), Grant/Research Support (Ongoing); Chiesi USA: Grant/Research Support (Ongoing)

Panel Discussant(s)

• 

  Paul A. Gurbel, MD, FSCAI

  Director
  Sinai Center for Thrombosis Research and Drug Development
  Baltimore, Maryland, United States

  Disclosure(s): No financial relationships to disclose
• 

  Adnan Kastrati, MD

  Senior Consultant, Head of Catheterization Laboratory
  Deutsches Herzzentrum Muenchen
  Munich, Bayern, Germany

  Disclosure(s): No financial relationships to disclose
• 

  Roxana Mehran, MD, FACC, FACP, FCCP, FESC, FAHA, MSCAI

  Professor of Cardiology and Population Health Science and Policy, Mount Sinai Endowed Professor in Cardiovascular Clinical Research and Outcomes; Director of Interventional Cardiovascular Research and Clinical Trials; Director of Women’s Heart and Vascular Center at Mount Sinai Heart
  Icahn School of Medicine at Mount Sinai, New York
  New York, New York, United States

  Disclosure(s): Abbott, Alleviant Medical, Beth Israel Deaconess Medical Center, Concept Medical, Cordis, Elixir Medical, Faraday Pharmaceuticals, Idorsia Pharmaceuticals, Janssen, MedAlliance, Mediasphere Medical, Medtronic, Novartis, Protembis GmbH, Sanofi, RM Glo: Grant/Research Support (Ongoing); AMA - JAMA Cardiology (Associate Editor), ACC (BOT Member, SC Member CTR Program): Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Elixir Medical, Stel, ControlRad (spouse): Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Elixir Medical, IQVIA, Medtronic, Medscape/WebMD Global, NovoNordisk: Consultant (Ongoing), Consulting Fees (e.g., advisory boards) (Ongoing); SCAI (Women in Innovations Committee Member), Faculty Cardiovascular Research Foundation (CRF), Women as One (Founding Director): SCAI (Women in Innovations Committee Member), Faculty Cardiovascular Research Foundation (CRF), Women as One (Founding Director) (Ongoing)